Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

Abstract Background Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain u...

Full description

Bibliographic Details
Main Authors: Yihai Liu, Jiamin Xu, Mingyue Wu, Biao Xu, Lina Kang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Lipids in Health and Disease
Subjects:
Atherosclerosis
Sodium‐glucose cotransporter 2 inhibitor
Empagliflozin
Sympathetic activity
Renin‐angiotensin‐aldosterone system
Online Access:https://doi.org/10.1186/s12944-021-01430-y

Internet

https://doi.org/10.1186/s12944-021-01430-y

Similar Items